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Summary In the present work we reviewed recent advances concerning
neuroprotective=neurotrophic effects of acute or chronic nicotine exposure,
and the signalling pathways mediating these effects, including mechanisms
implicated in nicotine addiction and nAChR desensitization. Experimental
and clinical data largely indicate long-lasting effects of nicotine and nicotinic
agonists that imply a neuroprotective=neurotrophic role of nAChR activation,
involving mainly a7 and a4b2 nAChR subtypes, as evidenced using selective
nAChR agonists. Compounds interacting with neuronal nAChRs have the
potential to be neuroprotective and treatment with nAChR agonists elicits
long-lasting neurotrophic effects, e.g. improvement of cognitive performance
in a variety of behavioural tests in rats, monkeys and humans. Nicotine
addiction, which is mediated by interaction with nACh receptors, is believed
to involve the modification of signalling cascades that modulate synaptic
plasticity and gene expression. Desensitization, in addition to protecting cells
from uncontrolled excitation, is recently considered as a form of signal
plasticity. nAChR can generate these longe-lasting effects by elaboration of
complex intracellular signals that mediate medium to long-term events crucial
for neuronal maintenance, survival and regeneration. Although a comprehen-
sive survey of the gene-based molecular mechanisms that underlie nicotine
effects has yet not been performed a growing amount of data is beginning to
improve our understanding of signalling mechanisms that lead to neurotrop-
hic=neuroprotective responses. Evidence for an involvement of the fibroblast
growth factor-2 gene in nAChR mechanisms mediating neuronal survival,
trophism and plasticity has been obtained. However, more work is needed to
establish the mechanisms involved in the effects of nicotinic receptor subtype
activation from cognition-enhancing and neurotrophic effects to smoking
behaviour and to determine more precisely the therapeutic objectives in po-
tential nicotinic drug treatments of neurodegenerative diseases.
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Nicotinic acetylcholine receptors
Neuronal nicotinic acetylcholine receptors (nAChRs) be-
long to the superfamily of ligand-gated ion channels and
are located in both the peripheral and central nervous sys-
tems. They are composed of five subunits and at present
nine nicotinic receptor a subunits (a2–a10) and three b
subunits (b2–b4) have been identified, each encoded by a
different gene (Picciotto et al., 2001). In heterologous ex-
pression nAChR can contain more than one of the a2,
a3, a4 or a6 subunits and=or both b2 and b4 subunits as
well (Couturier et al., 1990). Accordingly, several different
combinations of nAChR subunit mRNA and=or proteins
have been identified in the central and peripheral nervous
structures (Le Novere et al., 2002). The subunits a7, a8,
a9, and a10 subunits can form homomeric receptors (Le
Novere and Changeux, 1995). These multiple combinations
of nAChR subunits possess distinct pharmacological and
physiological properties. Thus nAChRs show different affin-
ity for ligands, variability of permeability for cations and
rate of desensitization (Changeux et al., 1998).
The distribution of neuronal nAChR in the CNS differs
for the different subunits and the most common subunit
arrangements within the central nervous system include
the a4=b2 type receptor and the a7 type receptor. The a4
and b2 are present in the entire nervous system (Wada
et al., 1989). By contrast the distribution of a7 subunit
mRNA is restricted to certain layers of cerebral cortex, to
the hypothalamus, hippocampus and to some brain stem
nuclei (Seguela et al., 1993). nAChR containing other sub-
units are localized in important brain regions, but they are
less abundant. The a2 subunit is expressed at very low
levels in restricted brain regions (Wada et al., 1989). The
a5 subunit mRNA is expressed at high levels in neurons
of the subiculum, pre- and parasubiculum, substantia nigra,
ventral tegmental area, and weakly expressed in the cerebral
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cortex (Wada et al., 1990). The a3 and b4 subunits, which
form the main nAChR responsible for nicotinic synaptic
transmission in autonomic ganglia, are highly enriched in
the medial habenula (Le Novere and Changeux, 1995). The
a6 and b3 subunits are highly and selectively enriched in
catecolaminergic nuclei, such as the dopaminergic neurons
of the substantia nigra, and the noradrenergic neurons of
the locus coeruleus (Le Novere and Changeux, 1995). It
has therefore been proposed that they can form, together
with other subunits, the nAChR responsible for catechol-
amine release in the basal ganglia and hippocampus (Le
Novere and Changeux, 1995). nAChRs located presynapti-
cally regulate the release of serotonin, dopamine, norepi-
nephrine (Summers and Giacobini, 1995), glutamate (Gray
et al., 1996), gamma-aminobutyric acid (Ji and Dani, 2000)
and acetylcholine (Tani et al., 1998). The a4=b2 nicotinic
receptor binds nicotine with high affinity, while the a7
nicotinic receptor binds nicotine with a low affinity (Lena
and Changeux, 1998). When agonists bind to the nAChR,
the receptor complex undergoes a conformational change
in its structure, which allows the channel gate to open,
permitting the passage of cations through the channel pore.
However functionally, the nAChR complex can exist in
three conformational states, which are dynamically regu-
lated by exposure to the agonist: closed, open and desensi-
tized states.
Neuroprotective=neurotrophic effects of nAChR
activation
Recently an increasing number of potent nAChR agonists
have been used in experimental research and clinical trials,
and have been found displaying efficacy and=or a more
selective affinity than nicotine for neuronal nAChR sub-
types, some of which are considered potential candidates
not only for the treatment of neurodegenerative disease such
as Alzheimer’s disease (AD) and Parkinson’s disease (PD)
(Bannon et al., 1998), but also, as discussed below, for cog-
nitive disorders associated with Schizophrenia (Kem, 2000).
A growing number of in vivo and in vitro findings have
shown that nAChRs activation have the potential to be
neuroprotective=neurotrophic.
Evidence in vivo
nAChRs have important roles in development and synaptic
plasticity (Broide and Leslie, 1999; Levin et al., 1999). a7
nAChRs are expressed early in development and have been
shown to be important for the control of neurite outgrowth,
and are involved in events of synaptic remodelling in the
adult nervous system (Pugh and Berg, 1994). The high
concentration of a7 receptors in the hippocampus, a region
of the brain that is critical for memory, also supports a role
for a7 receptors in the modulation of synaptic plasticity
and in memory formation (Small et al., 2001). Nicotinic
receptors can modulate the rhythmic activity important for
synaptic plasticity, the basis for learning and memory
(Huerta and Lisman, 1993).
Many studies have analysed the effect of nAChR ago-
nists and antagonists on cognitive performance in a vari-
ety of behavioural tests in rats, monkeys and humans, and
their specific involvement in cognitive function, such as
attention, learning, sensory perception, memory consoli-
dation and arousal has been reported (Levin and Simon,
1998). The nAChR agonist nicotine improves cognition
for prolonged periods in non-human primates and in
rodents even after nicotine discontinuation (Gould and
Stephen, 2003; Buccafusco et al., 2005). By contrast, a
blockade of nicotinic receptors by a nicotinic receptor
antagonist impairs memory function (Levin and Rezvani,
2000).
Performance in attention and working memory tasks is
improved by nicotine (Gioanni et al., 1999; Levin et al.,
2002), and involves multiple brain areas, such as hip-
pocampus, amygdala, and particularly the prefrontal cor-
tex that has been implicated in attention and working
memory and goal-directed behaviour (Groenewegen and
Uylings, 2000). Epibatidine has been found to induce Long-
term potentiation (LTP), improve memory and learning in
human and experimental animal models and to be neuro-
protective in several in vitro models (Jonnala et al., 2002)
and both a7 and a4b2 nAChRs are essential for these
effects. The GTS-21 nicotinic agonist with potent func-
tional selectivity for the a7 nAChR subtype improves mem-
ory performance in several tests, such as one-way active
avoidance, Lashley III maze testing, and 17 arm radial maze
test performance in aged rats, and improve cognitive and
perceptual disturbances in schizophrenia (Arendash et al.,
1995). The nicotinic agonist SIB-1508Y, selective for
a4b2, and the nicotinic agonist SIB-1553A, active at b4
nAChRs, exhibit ability to improve cognitive activity and
learning in a variety of models and to promote locomotor
activity (Vernier et al., 1999), with long-lasting effects, in
chronic low-dose MPTP-treated monkeys (Schneider et al.,
2003). In addition, functional magnetic resonance imaging
studies have shown increased activation of frontal net-
works by nicotine administration during attention tasks
(Lawrence et al., 2002). Nicotinic receptor function may
also be critical for maintenance of cognitive function dur-
ing aging. Increased neurodegeneration is seen in aged
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b2 subunit knockout mice and is associated with learn-
ing deficits as shown during different conditioning tasks
(Picciotto et al., 2001).
The mechanism of the persisting effects of nAChR acti-
vation is currently unknown, although the involvement of
an alteration in nAChR expression or of interactions with
other transmitter systems has been suggested (Levin and
Simon, 1998). Recently we have taken into consideration
the possibility that this persistence of nicotine effects could
also be related to the increased levels of neurotrophic fac-
tors observed following nAChR agonist treatment in differ-
ent experimental models (Belluardo et al., 1998, 1999b,
2000).
Neuroprotective effects of nAChR activation have been
shown in different models with lesions of septohippo-
campal or nigrostriatal systems. Nicotinic agonists protect
against neocortical neuronal cell loss induced by nucleus
magnocellularis lesions in the rats and delayed hippocam-
pal CA1 subregion neuronal death by ischemia (Nanri
et al., 1998) and against septal cholinergic neurons death
following fimbrial transaction (Martin et al., 2004), and
septohippocampal lesion with induced deficits in spatial
memory (Decker et al., 1994b, 1995) or working memory
(Levin et al., 1993). Prenatal nicotine exposure resulted in a
trophic influence on cerebral cortex development character-
ized by premature increases in cholinergic projections
based on analysis of choline acetyltransferase (Navarro
et al., 1989).
Chronic nicotine treatment counteracts the disappear-
ance of tyrosine-hydroxylase-immunoreactive or elimi-
nates asymmetry in striatal glucose utilization in the
mesostriatal dopamine system after partial hemitransec-
tion in the rat (Janson et al., 1988a, 1989; Janson and
Moller, 1993; Jeyarasasingam et al., 2002), and protects
against neurodegeneration of dopaminergic neurons in the
MPTP model (Janson et al., 1988b) and the meth-amphet-
amine mice model of Parkinson’s disease (Maggio et al.,
1998).
Evidence in vitro
There exist numerous model systems in which nicotine has
shown protective effects on neurons, including exposure
to cytotoxic insults of glutamate, b-amyloid or 6-OHDA
(Ryan et al., 2001). Nicotine induces protection of cultured
cortical and striatal neurons against cytotoxicity mediated
by NMDA and AMPA receptors (Kaneko et al., 1997), and
of cultured hippocampal and cerebellar neurons against
kainic acid induced neurotoxicity (Semba et al., 1996).
This nAChR neuroprotection against glutamate cytotox-
icity seems to be mediated by their inhibitory action on
NO-formation (Shimohama et al., 1996). Other studies
have shown that nicotine rescues PC12 cells from death
induced by NGF deprivation (Jonnala et al., 2002). Nico-
tine has recently been shown to inhibit Ab aggregation by
preventing the conversion from a- helix to b-sheet confor-
mations (Salomon et al., 1996). Nicotine was found to
prevent Ab toxicity in hippocampal neurons (Zamani and
Allen, 2001) and in cortical neurons (Shimohama and
Kihara, 2001), and it has been suggested that nicotine-
induced protection from Ab toxicity is mediated by the
phosphatidylinositol 3-kinase cascade (Kihara et al., 2001).
Nicotine also inhibits Ab induced phospholipase A2 acti-
vation (Singh et al., 1998). Taken together the results of
nicotine inhibition of Ab toxicity in cell culture suggested
the possibility that the nAChR may be a therapeutic target
in AD.
Clinical evidence
Parkinson’s disease and Alzheimer disease – Epidemiological
and clinical studies have for a long time suggested a poten-
tial neuroprotective=neurotrophic role of nicotine in neu-
rodegenerative disease, such as AD and PD (Quik, 2004;
Newhouse et al., 2004). During the progression of AD,
cholinergic inputs degenerate and the number of nAChRs
in some areas decreases (Gotti and Clementi, 2004) and
high affinity nAChR of the a4b2 subtype, are significantly
lost in AD (Court et al., 2001). This loss likely occurs early
in the disease and is probably not true for a7-nAChR
(Martin-Ruiz et al., 1999) although a loss of a7-nAChRs
in AD has been reported (Banerjee et al., 2000). This loss
of nicotinic mechanisms, which modulates the gain and
accuracy of synapses and modulates the excitability of cir-
cuits, is likely to contribute to the overall cognitive deficits
associated with AD. Therefore cognitive changes in AD, in-
cluding memory loss, are also likely to be caused by changes
in synaptic plasticity in addition to non-specific neurotoxicity
and=or cell loss (Small et al., 2001).
Clinical studies have revealed that nicotine is effective in
ameliorating memory and attention deficits in AD patients
(Newhouse et al., 2001), and to improve learning and mem-
ory in normal humans (Warburton et al., 1986). Numerous
studies now demonstrate that chronic nicotine exposure
induces increased numbers of CNS nAChR in animals
and in human smokers in vivo (Wonnacott, 1990) and this
up-regulation of receptor number has been proposed to be
responsible for nicotine’s neuroprotective action (Jonnala
and Buccafusco, 2001). ABT-594 and ABT-418, potent and
selective agonists for the a4b2 subtype (Bannon et al.,
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1998) are 3–10-fold more potent than nicotine as to mem-
ory-enhancing actions (Decker et al., 1994a) and improve
in subjects with moderate AD deficits in total recall in a
verbal learning task, in a selective reminding task, and in
non-verbal tasks such as spatial learning and memory and
repeated acquisition.
Treatments with cholinesterase inhibitors, such as phy-
sostigmine, have shown cognitive improvements (De La
Garza, 2003). Recently galantamine, a modest acetylcholi-
nesterase inhibitor and allosteric potentiating ligand at
nAChRs, has shown neuroprotective effects against a vari-
ety of cytotoxic agents, such as b-amyloid, glutamate and
sustained cholinergic stress in vivo (Geerts, 2005) and ef-
fects on memory, hippocampal plasticity, and elevates the
number of nicotinic receptors within the hippocampus and
neocortex (Barnes et al., 2000). In patients with AD, galan-
tamine improves cognitive functional and behavioural
symptoms (Maelicke et al., 2001). There is ample evidence
that these effects of galantamine are mediated through
allosteric potentiation of the a7 subunits with the addi-
tional benefit of a lower degree of receptor desensitization
(Maelicke et al., 2001). Taken together, the loss of nAChRs
associated with AD, with the ability of nicotine to upregu-
late its receptors and the epidemological data showing
smokers to be at less risk of AD than non smokers, are
consistent with the hypothesis of nicotine receptor involve-
ment in neuroprotective=neurotrophic functions (Perry et al.,
1999).
Like for AD an inverse association between cigarette
smoking and PD has been reported (Baron, 1986). Accord-
ing to epidemiological studies, it has been shown that
cigarette smoking may have therapeutic implications in
PD (Baron, 1986) with substantial improvement of the PD
symptoms (Kelton et al., 2000), and acute i.v. nicotine
improved reaction time, speed of processing and tracking
errors, but not selective attention and semantic retrieval
(Fratiglioni and Wang, 2000). Based on the epidemiologi-
cal studies and the neuroprotective actions of nicotine in
animal models of PD (Janson et al., 1988a, b; Fuxe et al.,
1990) the potential role of nAChRs as targets for treatment
of this disease has been raised (Belluardo et al., 2000;
Burghaus et al., 2003), including the specific treatment of
cognitive dysfunction associated with PD (Forgacs and
Bodis-Wollner, 2004). Some of these effects on learning
and memory may not only be caused by neurotrophic
actions by nicotine and other nicotinic receptor agonists,
but may also be mediated by the enhancement of dopami-
nergic and noradrenergic function via the ability of nico-
tinic receptor agonists to enhance the release of dopamine
and norepinephrine in the brain including the striatum
(Summers et al., 1997; Andersson et al., 1981; Fuxe et al.,
1989), as well as to increases in tyrosine hydroxylase
and dopamine b-hydroxylase mRNA levels (Gueorguiev
et al., 2000). Therefore, treatment with nicotine, or pref-
erably selective nicotinic agonists, could attenuate nigro-
striatal damage and reduce PD progression and thus
provide neuroprotective effects by selectively stimulating
nAChR subtypes as well as improve PD symptoms by in-
creasing dopamine release and synthesis (Kelton et al.,
2000; Lichtensteiger et al., 1982; Kita et al., 1992;
Andersson et al., 1981; Fuxe et al., 1986).
Schizophrenia – Over the last twenty years, a high inci-
dence of smoking has been observed in subjects suffering
from schizophrenia (Sacco et al., 2004) and clinical data
suggested that nicotine improves certain cognitive and sen-
sory abnormalities associated with schizophrenia such as
deficits in sensory gating (Ripoll et al., 2004; Tanabe et al.,
2005). Data available suggested that nicotine improves
attention and inhibitory functions in hippocampus and cin-
gulate gyrus with involvement of GABAergic mechanisms
(Tanabe et al., 2005). Furthermore, a partial a7 agonist im-
proves auditory P50 suppression in schizophrenia (Koike
et al., 2005) and it has been indicated to be reasonable
candidates for the treatment of cognitive and perceptual
disturbances in schizophrenia (Koike et al., 2005; Deutsch
et al., 2005), since inter alia a7 nicotinic receptor activa-
tion may create a glutamatergically mediated increase in
dopamine release in the prefrontal cortex, and in area impli-
cated in the development of negative symptoms in patients
with schizophrenia (Nomikos et al., 2000). Recent studies
have shown that also galantamine improves the cognitive
performances of patients with refractory schizophrenia hav-
ing auditory hallucinations and a disorganized form of
schizophrenia (Allen and McEvoy, 2002). Therefore, the
alleviation of certain symptoms of some forms of schizo-
phrenia induced by nicotine could explain the high incidence
of smoking among schizophrenic patients and suggests that
nicotine intake by cigarette consumption may be a form
of self-medication. It is of substantial interest that there
exists a differential modulation of gene expression in
NMDA postsynaptic densities in schizophrenic smokers
vs. control smokers (Mexal et al., 2005). It is also possible
to conceive that neurotrophic actions of nicotinic agonists
can be involved in antischizophrenic actions in view of the
neurodevelopmental theory of schizophrenia (Lipska, 2004;
Freedman, 2005), since nicotinic receptors and FGF-2 exist
in the subependymal layer rich in neuronal progenitor cells
(Mudo’ et al., 2005).
Taken together the available experimental and clinical
data largely indicate long-lasting beneficial effects of nico-
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tine and nicotinic agonists that imply a neuroprotective=
neurotrophic role of nAChR activation, giving these recep-
tors a therapeutic role in PD and AD. In addition, a7 ago-
nists may have a therapeutic potential in schizophrenia.
Nicotine addiction and neuroplasticity
Brain nAChRs distribute to postsynaptic, as well as to pre-,
peri- and other, sites, where they may modulate the neuro-
transmitter release, synapse action and neuronal activity, play-
ing important roles in many physiological processes including
neuron development, learning and memory, and reward
responses as well as in addiction development (Dani et al.,
2001). Addictive drugs produce forms of structural plasticity
similar to those associated with other forms of experience-
dependent plasticity. Nicotine addiction, which is mediated by
interaction with nAChRs, is believed to involve the modifica-
tion of signalling cascades that modulate synaptic plasticity
and gene expression, as proposed for other drugs of abuse
(Dani et al., 2001; Nestler, 2002).
A growing body of evidence has shown that drugs of
abuse can activate memory mechanisms in the circuits of
the mesolimbic reward center (Nestler, 2001; Samaha and
Robinson, 2005). It has been reported that nicotine in the
ventral midbrain (VTA), via MLA-sensitive nAChR, stim-
ulates both glutamatergic terminals and DA neurons
directly, potentiating excitatory transmission in the VTA
and replace presynaptic stimulation completely in LTP
induction, generating synaptic plasticity (Mansvelder
and McGehee, 2000). The glutamatergic input to the DA
neurons can undergo LTP in response to pairing of pre-
and postsynaptic stimulation, and this process is depen-
dent on NMDA receptor activation (Bonci and Malenka,
1999).
A limited exposure to nicotine is sufficient to induce
lasting changes in the circuitry of the mesolimbic DA
reward system as shown in human adolescents express-
ing behaviours that support the observations of lasting
changes in synaptic activity by a single exposure to nico-
tine (Mansvelder and McGehee, 2000), or initial symptoms
of nicotine dependence after smoking of only a few ciga-
rettes (DiFranza and Wellman, 2003). Early on acute
nicotine injections and acute intermittent exposure to ciga-
rette smoke was found to increase DA turnover and release
in certain limbic DA nerve terminal systems of the nucleus
accumbens and the olfactory tubercle (Andersson et al.,
1981; Fuxe et al., 1986). With continued nicotine exposure,
plastic molecular alterations in central DA systems might
underlie the continued propensity to consume nicotine by
inducing craving, the aversive effects of withdrawal, and
aberrant incentive-salience attribution to environmental stim-
uli that are associated with nicotine. The synaptic mech-
anisms that nicotine activates within the DA reward system
are likely to underlie the early steps of nicotine dependence
and it is one of the critical areas for future research on the
physiological basis of nicotine addiction (Pulvirenti and
Diana, 2001).
Desensitization: neuroprotection and plastic changes
Work from several laboratories show that when ACh, nico-
tine or related agonists are continuously applied nAChRs
become ‘desensitized’ or temporarily inactive (Giniatullin
et al., 2005). Desensitization in addition to protecting cells
from uncontrolled excitation is recently considered as a
form of signal plasticity that might modify synaptic effi-
cacy in various brain regions (Dani et al., 2001; Mansvelder
and McGehee, 2002). In fact, the most obvious neuropro-
tective action of desensitized nAChRs is to inhibit exces-
sive excitation dependent on high permeability to Caþþ of
activated nAChRs. In line with this, mutation at the posi-
tion leucine 247 of the a7 subunit significantly inhibits
desensitization and inserting this mutation into mice can
induce animal death (Wang and Sun, 2005). Recently, a
reasonable working hypothesis has been developed stating
that the phenomena of desensitization beyond simply nico-
tinic receptor inactivation may contribute to the array of
potential effects associated with chronic nicotine exposure.
Numerous studies have demonstrated that chronic nicotine
exposure induces increased numbers of CNS nAChRs both
in vivo in animals and in human smokers, caused by post-
translational mechanisms (Benwell et al., 1988), and in vitro
(Bencherif et al., 1995), although other investigations sup-
port a change not in the number of receptors but in their
state of binding and response to ligands (Vallejo et al.,
2005). This nicotine up-regulation of receptor number is
viewed as responses to desensitization thereby also im-
plying that the desensitized nAChRs may be responsible
for the nicotine’s neuroprotective action (Jonnala and
Buccafusco, 2001). The mechanism may also involve an
enhanced intracellular maturation of the nicotinic receptors
(Sallette et al., 2005). Pretreatment with nicotine for 24 h
has been shown to alleviate the toxic actions of MPTP,
indicating a neuroprotective effect of desensitized nAChRs,
and the neuroprotective action of nicotine in cultured PC12
cells has been suggested to be due to upregulation of a7-
containing nAChRs following their persistent desensitiza-
tion (Jonnala and Buccafusco, 2001). According to this
finding, it has been reported that desensitized a7 nAChRs
have a neuroprotective function through modulating signal
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transduction pathways (Dajas-Bailador et al., 2000; Dani,
2001).
A consistent number of reports suggested that the desen-
sitized nAChRs induced by chronic nicotine may be im-
portant for learning and memory (Lindstrom et al., 1987).
In this context, acute or prolonged chronic nicotine treat-
ment can decrease the threshold for LTP induction in
the hippocampus CA1 and can reverse the age-dependent
decrease in LTP-induction (Fujii and Sumikawa, 2001).
Because a decreased threshold for LTP may be mimicked
by MLA and prevented by a non a7 nAChR blocker, it has
been suggested that a7 nAChR desensitization are mainly
responsible for the effects (Fujii and Sumikawa, 2001).
Furthermore, in view of the negative association between
cigarette smoking and PD or AD, it has also been suggested
that desensitized nAChRs may be responsible for their
neuroprotective actions (Baron, 1996). The use of allosteric
modulator drugs that do not act as agonists on nAChRs,
and therefore cannot generate their widespread desensiti-
zation (Maelicke et al., 2000) may be important tools
for understanding the role of receptor desensitization in
neuroprotection.
Molecular mechanisms mediating neuroprotective
effects of nAChR activation
Nicotine and other nAChR agonists as above described
have neuroprotective=neurotrophic effects in several in vivo
and in vitro models of neuronal death (O’Neill et al., 2002).
Nevertheless, intracellular steps that mediate these effects
of nAChR ligands are not fully solved.
Concerning neuroprotective effects, nAChR activation
evoking Caþþ influx is likely to represent a first step in
the intracellular signalling cascades (Dajas-Bailador et al.,
2000) followed by diverse downstream pathways and pro-
cesses that are subsequently activated. Thus, this activation
of downstream signalling pathways appears necessary for
the prevention of neuronal death. Consistent with this
suggestion, block of Caþþ influx following activation of
a7 nAChR promotes survival of spinal cord motoneurons
from programmed cell death (Messi et al., 1997). In hippo-
campal slices nicotine-induced protection against acute
NMDA damage is mediated by the activation of phosphat-
idylinositol 3-kinase and ERK=MAPK (Ferchmin et al.,
2003) or protein kinase C (Li et al., 1999) and regulation
of Bcl-2 and Bcl-x expression, which may be involved in
prevention of neuronal death (Toborek et al., 2000; Mai et al.,
2003). Other results suggested that nAChR stimulation
induces neuroprotection against glutamate cytotoxicity by
its inhibitory action on NO-formation (Shimohama et al.,
1996). Stimulation of nAChR can also lead to the increased
expression of neurotrophic factors (Belluardo et al., 2000).
Therefore, activation of diverse signalling mechanisms
might subsequently lead to neuroprotection through inhibi-
tion of apoptosis and=or increased expression of neuro-
trophic factors crucial for neuronal maintenance, survival
(Belluardo et al., 2000; Roceri et al., 2001).
Molecular mechanisms mediating neurotrophic
effects of nAChR activation
Regulation of gene expression by synaptic activity is essen-
tial both for normal development in the nervous system and
for long-term components of synaptic plasticity (Dajas-
Bailador et al., 2000). The chain of events connecting
synaptic activity and gene expression is often initiated
by calcium influx (Hardingham et al., 2001), and nAChRs,
and particularly the a7 nAChR, are permeable to Caþþ. In
neurons, nAChRs activation can play a relevant role in Caþþ
signalling not only because of the Caþþ entry through differ-
ent nAChR subtypes, but also because nAChR depolariza-
tion of the plasma membrane can activate voltage operated
calcium channels and may also increase intracellular Caþþ
by inducing Caþþ mobilization from intracellular stores.
The absolute quantity and strategic localization of Caþþ
entry through nAChRs is likely to be relevant for the reg-
ulation of calcium-mediated downstream intracellular
events, including transmitter release, cell excitability, acti-
vation of protein kinases, gene expression, cell differentia-
tion and survival and new protein synthesis, ultimately
leading to changes in synaptic plasticity and neuronal re-
modelling (Dajas-Bailador et al., 2000). Therefore, in addi-
tion to rapid changes in membrane potential, activation of
nAChR can also generate longer-lasting effects in the
receptive neuron, which contribute to the elaboration of
complex intracellular signals that mediate medium-to long-
term events (Role and Berg, 1996).
nAChRs have been implicated in a wide variety of neuro-
trophic events, including learning and memory, which
involve mechanisms for calcium-dependent synaptic regula-
tion (Dajas-Bailador et al., 2000). nAChR agonists activate
mechanisms of synaptic plasticity and long-term enhance-
ment of memory, which involve an increase in the number
and efficiency of synaptic connections between neurons.
Long-lasting cognitive effects of nAChR ligands may be
attributed to the cellular changes that result in synaptic plas-
ticity and LTP is a model of the synaptic plasticity of learn-
ing and memory (Buccafusco et al., 2005).
During the past few decades, the pathways that are in-
volved in synaptic plasticity have been elucidated (Kandel,
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2001), particularly the phenomenon of LTP, which is an
increase in synaptic strength that can persist for extended
periods of time (Bliss and Lomo, 1973). The phases of LTP
correlate with the stages of memory, and impairment of
the mechanisms of LTP leads to memory deficits (Kandel,
2001). In the early phase of LTP, which lasts only hours,
Caþþ dependent second messenger systems modify existing
proteins to enhance neurotransmitter release from presynap-
tic neurons and support short-term memory. Late phases of
LTP require protein synthesis, lasting at least a day, and
require prolonged elevation of the intracellular Caþþ con-
centration. The latter activates a cascade that involves ade-
nylyl cyclase, cAMP and second messengers such as protein
kinase A and mitogen-activated protein kinase (MAPK)
(Impey et al., 1999). In turn, these events may enhance the
activity of transcription factors, e.g. the cAMP response
element-binding protein-1 (CREB-1), which increases the
expression of immediate early genes and stimulates the
synthesis of growth factors and other proteins that potentiate
cell excitability and support the formation of new synaptic
connections. The growth and maintenance of new synaptic
connections enables the persistence of long-term memory
(Kandel, 2001). Much evidence indicate that activation of
nAChRs may initiate a cascade of cellular signals that pro-
duces long-term molecular changes involved in the molecu-
lar mechanisms of memory. Repeated exposure to nAChR
agonists enhances LTP more than a single dose administra-
tion, whereas a persistent activation of nAChRs is not
required for the maintenance phase of LTP. These effects
of nAChR agonists have been characterized most exten-
sively in the hippocampus, where a7 nAChR activation
enhance the probability of LTP and might contribute to the
mechanisms that underlie the effects of nicotine on cognition
(Ji et al., 2001).
nAChR agonists may activate several mechanisms which
may induce long-term changes leading to more complex
neurotrophic response in addition to increased number and
efficiency of synaptic connections between neurons.
Nicotine treatment by increasing permeability of nAChR
to Caþþ can induce PKC activity (Fenster et al., 1999), and
CaþþCaM-dependent protein kinase II, and both effects
can be reversed by nAChR antagonists (Damaj, 2000).
The mitogen-activated protein kinase (MAPK or Erk1=2)
pathway can also be activated by nicotine-dependent in-
creases in Caþþ levels (Cox et al., 1996) or alternatively,
changes in MAPK activity might be regulated by nicotine-
dependent alterations in the levels of fibroblast growth fac-
tors that would activate tyrosine kinase receptor-mediated
pathways (Blum et al., 1996). Similarly, Nicotine-depen-
dent changes in phospholipase C (Pandey, 1996) and PKA
signalling pathways might also be mediated by upstream
effects of nicotine on neurotrophic factors or neurotrans-
mitter release.
Previous studies have demonstrated that nicotine admin-
istration modulated the expression of a variety of genes,
and transcriptional activation (Shim et al., 2000). Exposure
to nAChR agonists elevates the expression of the im-
mediate early genes c-Fos and JunB in several brain areas
(Harlan and Garcia, 1998). The immediate early genes reg-
ulate the transcription of downstream targets that have
diverse roles in signalling, cell growth and cell main-
tenance. Recently, Gene-array technology indicates that
nicotine administration might affect numerous genes, in-
cluding those involved in intracellular signalling, transcrip-
tion, translation, CREB phosphorylation (Gueorguiev et al.,
2004), transmitter receptors, ion channel signalling path-
ways (Sun et al., 2004) and proteins associated with RNA
binding and the plasma membrane (Dunckley and Lukas,
2003). We used Rat Genome U34A Affymetrix GeneChip
arrays to find in the rat parietal cortex new genes respon-
sive to acute intermittent nicotine treatment and linked to
neuroprotection (Belluardo et al., 2005). In this study 25
modified genes were selected and among them five genes
encoding transcription factors were found up regulated
(Nr4a1, Cebpg, Egr-1, Egr-2, JunB). All these transcription
factors show special significance in view of their known
role in regulation of several genes, some of which are
involved in neurotrophic and=or neuroprotective actions.
Among the intracellular events regulated by nAChR acti-
vation, the CREB and ERK=MAPK signalling cascades
have attracted particular attention because their activities
are central to long-term plasticity in the nervous system
(Sweatt, 2001). In fact, activation of ERK=MAPK is re-
quired for the formation of contextual and spatial memories
in mammals (Sweatt, 2001) and nAChR mediate the Caþþ-
dependent activation of ERK=MAPK and sustained phos-
phorylation of CREB in several neuronal models (Chang
and Berg, 2001). Nicotine can alter gene expression in rat
hippocampal neurons, as reflected by activation of the tran-
scription factor CREB and appearance of the immediate
early gene product c-Fos. The process depends on both
CaM and MAP kinases and on calcium release from inter-
nal stores (Hu et al., 2002). These findings in addition to
having directly physiological relevance in learning and
memory, may also have pathological relevance in addiction
(Nestler, 2002). Nicotine dependence, which is mediated
by interaction with nAChR, is likely to involve the mod-
ification of signalling cascades that modulate synaptic plas-
ticity and gene expression, as proposed for other drugs of
abuse (Nestler, 2001; Dani et al., 2001). Although there are
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few reports on the contributions of signalling pathways in
models of nicotine addiction, several studies have focused
on the modulation of CREB following chronic treatment with
nicotine. CREB activation is required for nicotine reward
(Walters et al., 2005) and nicotine withdrawal significantly
reduced the concentrations of CREB and phosphorylated
CREB in rat cortex and amygdala (Pandey et al., 2001). Phos-
phorylated CREB appears also to be decreased in the nucleus
accumbens in mice following chronic consumption of nico-
tine in their drinking water (Brunzell et al., 2003). Overall,
these results support a role for ERK and CREB activity
in neural plasticity associated with nicotine dependence.
nAChRs activation is involved on neurotrophic
factor gene expression
The mechanisms by which nicotinic signalling may regu-
lates gene expression are poorly understood, and it is not
known how such mechanisms interact with other calcium
dependent pathways controlling transcription. Therefore, a
comprehensive survey of the gene-based molecular mech-
anisms that underlie nicotine effects is yet to be performed.
During the last years we have begun a study aimed to
identify genes encoding neurotrophic factors targeted by
nAChR activation and to elucidate the signalling pathways
through which nAChR regulate their expression.
Several neuronal populations within the adult CNS re-
quire the presence of neurotrophic factors to maintain neu-
ronal function (Sofroniew et al., 1990) and survival (Barde,
1989). Long-term changes in synaptic plasticity are asso-
ciated with neurotrophic factors (Pang et al., 2004) and the
reduction in neurotrophic factor expression may result in
the neuronal atrophy seen in normal ageing or the neuronal
loss observed in neurodegenerative disorders such as AD
and PD (Connor and Dragunow, 1998). Therefore a neuro-
trophic factor gene regulation by nAChR signalling has
been also taken into consideration as a possible mecha-
nism involved in neuroprotective=neurotrophic effects by
nAChR activation.
We have analysed the effects of acute intermittent nico-
tine treatment on FGF-2 expression and the results obtained
(Belluardo et al., 1998) showed that treatment with acute
intermittent nicotine (four i.p. injections at intervals of
30 min; 1 mg=kg), or with other nicotinic agonists such
as epibatidine and ABT-594, lead to a substantial upregula-
tion of FGF-2 mRNA and protein levels in the cerebral
cortex, the hippocampal formation, the striatum and the
ventral midbrain. An extension of this model to the study
of aged rats (24 months old) showed that the nicotine-
induced increases of FGF-2 mRNA levels is preserved
during aging (Belluardo et al., 1999a, 2000). In cultured
chromaffin cells from bovine adrenal medullae stimulation
of nAChR increases FGF-2 gene expression (Stachowiak
et al., 1994). This nAChR-mediated increase in expression
of FGF-2 gene was mediated by adenylate cyclase or pro-
tein kinase C and dependent on nuclear interaction of trans-
activating factors with a novel cis-acting element (Moffett
et al., 1998). In order to elucidate the signalling pathways
through which nAChR regulate FGF-2 expression we focus
on transcription factors identifying a potential role of
CREB. We could verify the presence in the promoter of
the FGF-2 gene a CRE-site which is able to bind CREB
(unpublished data). This involvement of CREB is also sup-
ported by the ability of acute nicotine treatment to induce
phosphorylation of CREB, without a change in CREB
levels, and to increase activation of ERK-1 (unpublished
data), which suggests an involvement of Ras=mitogen-
activated protein kinase (MAPK) pathways.
This regulation of FGF-2 gene in turn can exert neuro-
trophic functions involving neuronal survival, trophism and
plasticity. FGF-2 exerts its pleiotropic effect through spe-
cific high- and low-affinity receptors named FGFR-1-4
(Belluardo et al., 1997). FGF-2 has been implicated to be
the potent neurotrophic factor that promotes mitosis and
differentiation of neuroblasts (Mayer et al., 1993), and neu-
ronal survival and neurite extension (Ferrari et al., 1989)
and protects cultured central neurons from different insults
(Cheng and Mattson, 1991). An in vivo protective role for
FGF-2 has been indicated by studies showing that FGF-2
can support the survival of cholinergic basal forebrain neu-
rons following fimbria transaction (Anderson et al., 1988),
dopaminergic neurons following MPTP toxicity (Chadi
et al., 1993) and hippocampal neurons following cerebral
ischemia (Nakata et al., 1993) or hippocampal damage
after excytotoxic injury (Mattson et al., 1989). Endogenous
expression of FGF-2 blocked by neutralizing antibodies
following unilateral suction lesions of the motor cortex
retards recovery from injury in rats (Rowntree and Kolb,
1997). A loss of FGF-2 in the substantia nigra in PD has
been reported (Tooyama et al., 1993). Transgenic mice
lacking FGF-2 showed a reduction in the neuronal density
in the motor cortex, with layer V more greatly affected
(Ortega et al., 1998), suggesting that FGF-2 controls mi-
gration, differentiation and survival especially of cortical
neurons (Dono et al., 1998). Recently FGF-2 has been im-
plicated in neurogenesis in adult rat brain (Kuhn et al.,
1997). In this context we revealed in the neuroepithelium
of the subventricular zone of the lateral ventricle in the adult
rat brain the existence of a trophic mechanism mediated by
FGF-2 and its receptor and regulated by nAChR, activation
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of which by acute intermittent nicotine treatment enhances
neuronal precursor proliferation (Mudo’ et al., 2005) Other
pieces of evidence that nAChRs may play a direct role in the
regulation of neurogenesis come from the reported decline
of hippocampal cell proliferation in mice lacking the b2
subunit (Harrist et al., 2004), and a decrease of neurogenesis
in the adult hippocampal formation following chronic nico-
tine self-administration (Abrous et al., 2002). These findings
suggest the possibility of in vivo regulation of neurogenesis
in the adult brain by nicotine agonists and may help to
develop treatment stimulating neurogenesis with important
therapeutic implication.
Several reports have showed that other neurotrophic
factors may be under regulation of nAChR activation.
Intra-hippocampal administration of nicotine increases
transiently NGF in the CA1 and dentate gyrus of the hip-
pocampus and PC12 neuronal cells exposed to nicotine
increase NGF receptor expression (Jonnala et al., 2002).
Acute intermittent nicotine treatment increase levels of
BDNF in the rat striatum (Maggio et al., 1998), although
other reports in similar experimental models have indicated
as unchanged the BDNF levels (Belluardo et al., 1999a).
NGF itself enhances ACh release (Lapchak et al., 1994),
increases mRNA that encodes nAChR subunits (Henderson
et al., 1994) and promotes sprouting of ACh-containing
fibers in the septum (Heisenberg et al., 1994). Nevertheless,
in contrast to NGF, which is expressed only in restricted
regions of brain and does not give account for the large
effects of nicotine in several brain regions, FGF-2 is widely
distributed in the adult CNS both in neuronal and non
neuronal cells (Fuxe et al., 1996) and the potent and wide-
spread activation of FGF-2 in several brain regions follow-
ing nicotine treatment suggested that the cholinergic
activation of the FGF-2 gene via nAChR may be better
suited to participate in the plasticity changes and improved
neuronal survival in the brain found after nicotine agonist
treatment. Therefore, this FGF-2 nicotine activation sup-
ports the suggestion that the previously observed neuropro-
tective effects of nicotine and the potential beneficial
effects of nicotine agonists in the treatment of AD and
PD, may at least in part involve an activation of the neu-
ronal and glial FGF-2 signalling.
Conclusions
Although the large amount of data acquired in the last years
have added new important insight in our understanding the
molecular mechanisms that underlie nicotine effects, more
work is needed to establish the mechanisms involved in
any nicotinic receptor activation effects, from cognition-
enhancing effects to smoking behaviour, and to determine
more precisely the therapeutic objectives in potential nic-
otinic drug treatment of neurodegenerative diseases. In addi-
tion, it will be also important to determine how the diverse
nAChR subtypes are integrated in such actions and the
impact of their changes for pathology, and to define whether
neuroprotective=neurotrophic and cognitive enhancements
are mediated via acute activation, repetitive activation, or
more chronic inactivation of nAChR function or by some
combination of these actions. Such knowledge is important
for the development of targeted drug therapies acting on
nAChRs to delay the onset and progression of chronic age
related brain neurodegenerative pathologies, as seen in PD
and AD, leading to improvement of cognitive abilities.
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